EMA Authorised: Ebglyss (Lebrikizumab) — Almirall, S.A.

View source ↗

Summary

EMA authorised Ebglyss (Lebrikizumab) for atopic dermatitis, with Almirall, S.A. as the marketing authorisation holder. Decision date: 14 January 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• EBGLYSS (LEBRIKIZUMAB-LBKZ)

Snippet

Status: Authorised. Therapeutic area: Dermatitis, Atopic. MAH: Almirall, S.A.. Decision date: 14/01/2026